Genocea Biosciences Inc (NASDAQ:GNCA) was the recipient of a large decrease in short interest during the month of February. As of February 28th, there was short interest totalling 1,324,729 shares, a decrease of 46.0% from the February 15th total of 2,451,386 shares. Approximately 6.4% of the shares of the company are short sold. Based on an average daily volume of 729,413 shares, the short-interest ratio is currently 1.8 days.
Genocea Biosciences (GNCA) opened at $1.18 on Wednesday. The company has a quick ratio of 0.83, a current ratio of 0.83 and a debt-to-equity ratio of -1.26. The stock has a market cap of $94.53, a P/E ratio of -0.60 and a beta of 1.31. Genocea Biosciences has a 1-year low of $0.79 and a 1-year high of $7.29.
Genocea Biosciences (NASDAQ:GNCA) last posted its quarterly earnings data on Friday, February 16th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.03. analysts anticipate that Genocea Biosciences will post -0.59 EPS for the current fiscal year.
Several research analysts have commented on GNCA shares. Robert W. Baird started coverage on shares of Genocea Biosciences in a research report on Monday, February 12th. They issued an “outperform” rating and a $3.00 target price for the company. Cantor Fitzgerald started coverage on shares of Genocea Biosciences in a research report on Monday, March 5th. They issued an “overweight” rating and a $5.00 target price for the company. HC Wainwright started coverage on shares of Genocea Biosciences in a research report on Thursday, March 8th. They issued a “buy” rating and a $5.00 target price for the company. Needham & Company LLC upgraded shares of Genocea Biosciences from a “hold” rating to a “buy” rating and set a $3.00 target price for the company in a research report on Tuesday, February 6th. Finally, Zacks Investment Research cut shares of Genocea Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, January 3rd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company’s stock. Genocea Biosciences has an average rating of “Buy” and a consensus price target of $4.41.
TRADEMARK VIOLATION NOTICE: “Genocea Biosciences Inc (GNCA) Short Interest Update” was originally published by Ticker Report and is owned by of Ticker Report. If you are reading this article on another website, it was stolen and republished in violation of US & international trademark & copyright legislation. The legal version of this article can be viewed at https://www.tickerreport.com/banking-finance/3260648/genocea-biosciences-inc-gnca-short-interest-update.html.
Genocea Biosciences Company Profile
Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.